SphingoGene, Inc. is a cancer therapeutic development company focused on sphingolipid metabolism, which is recognized as a key factor in tumor cell survival and metastasis. Sphingogene scientists have developed a portfolio of highly potent small molecule drugs that can affect this pathway and have established a substantial worldwide patent position in the field. A few of the Company’s drugs are in late stage pre-clinical development and have demonstrated highly significant results to date. The Sphingogene team is comprised of the world’s experts in the field of sphingolipid metabolism and through its partners and advisors the Company has access to the industry’s leading cancer drug commercialization resources.
For additional information please contact:
Dr. James Norris, President & CEO